- Home
- FOXF vs CTNM Comparison
FOXF vs CTNM Comparison
Compare FOXF & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOXF | CTNM |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.2M | 507.0M |
| IPO Year | 2013 | 2024 |
Fundamental Metrics
Financial Performance| Metric | FOXF | CTNM |
|---|---|---|
| Price | $16.83 | $12.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $29.20 | $19.00 |
| AVG Volume (30 Days) | ★ 806.6K | 275.9K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,467,321,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $3.35 |
| 52 Week High | $31.18 | $16.33 |
Technical Indicators
Market Signals| Indicator | FOXF | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 39.88 |
| Support Level | $15.36 | $10.39 |
| Resistance Level | $17.98 | $13.18 |
| Average True Range (ATR) | 0.72 | 1.15 |
| MACD | 0.04 | -0.26 |
| Stochastic Oscillator | 56.80 | 18.46 |
Price Performance
Historical ComparisonAbout FOXF Fox Factory Holding Corp.
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.